Evidence map›Paper›PMID 41966749›Full record

ArticleNeoplasia (New York, N.Y.)2026

Assessing axitinib-induced differential responses in tumor vascularization and oxygenation with combined optoacoustic angiography and diffuse optical spectroscopy.

Anna Orlova, Ksenia Akhmedzhanova, Anna Glyavina, Alexey Kurnikov, Dmitry Khochenkov, Yulia Khochenkova, Artemii Korobov, Artur Volovetskiy, Andrey Yudintsev, Anastasiya Nerush and 6 more

Abstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anna OrlovaDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia.
Ksenia AkhmedzhanovaDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia; Department of Biophysics, Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Anna GlyavinaDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia; Department of Biophysics, Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Alexey KurnikovDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia.
Dmitry KhochenkovLaboratory of Biomarkers and Mechanisms of Tumor Angiogenesis, Research Institute of Experimental Diagnostics and Therapy of Tumors, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia; Center for Medical Chemistry, Institute of Chemistry and Energy, Togliatti State University, Togliatti, Russia.
Yulia KhochenkovaLaboratory of Biomarkers and Mechanisms of Tumor Angiogenesis, Research Institute of Experimental Diagnostics and Therapy of Tumors, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Artemii KorobovDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia; Center for Photonic Science and Engineering, Skolkovo Institute of Science and Technology, Moscow, Russia.
Artur VolovetskiyLaboratory of Molecular Pharmacology, Institute of Molecular Theranostics, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia.
Andrey YudintsevDepartment of Biophysics, Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Anastasiya NerushDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia.
Anna MaslennikovaDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia; Department of Biophysics, Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Vladimir VodeneevDepartment of Biophysics, Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Ilya TurchinDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia.
Wei LiuOptical Imaging Laboratory, Harbin Institute of Technology, Shenzhen 518055, China.
Daniel RazanskyInstitute for Biomedical Engineering and Institute of Pharmacology and Toxicology, Faculty of Medicine, UZH Zurich, Zurich, Switzerland; Institute for Biomedical Engineering, Department of Information Technology and Electrical Engineering, ETH Zurich, Zurich, Switzerland. Electronic address: daniel.razansky@uzh.ch.
Pavel SubochevDepartment for Radiophysical Methods in Medicine, A.V. Gaponov-Grekhov Institute of Applied Physics RAS, Nizhny Novgorod, Russia. Electronic address: pavel.subochev@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efficacy of antiangiogenic treatments is often linked to the complex interplay between tumor vascularization and oxygenation. Yet their relationship remains difficult to assess in vivo due to limitations of conventional clinical imaging techniques. We used a combination of noninvasive optoacoustic (OA) angiography and diffuse optical spectroscopy (DOS) to investigate the effects of the antiangiogenic therapy on vascular structure and oxygenation in subcutaneous xenograft model of Colo320 colon adenocarcinoma. Axitinib, a tyrosine kinase inhibitor targeting VEGF receptors, was administered into animals at 50 mg/kg, five days per week for four weeks. Raster-scan OA imaging was performed using 532 nm pulsed laser source and a wideband polyvinylidene difluoride (PVDF) detector. DOS measurements were conducted using a fiber-optic-based reflectance system. Immunohistochemical (IHC) analysis for CD31 and the hypoxia marker pimonidazole was used for validation. Axitinib treatment resulted in a thirtyfold reduction in the median tumor volume. OA imaging revealed reductions in volumetric vessel fraction and projected vessel area, while DOS showed a transient increase in blood oxygen saturation. IHC confirmed a decrease in microvessel density post-treatment and indicated larger hypoxic areas in treated tumors compared to controls at the experimental endpoint. The newly introduced approach thus facilitates experimental studies aiming at optimization of antiangiogenic treatment regimens and their subsequent combination with other treatment modalities, such as radiation therapy, where effectiveness may strongly depend on the vascular network condition and tumor oxygenation levels.

Indexed as

AngiographyImidazolesIndazolesNeovascularization, PathologicOxygenPhotoacoustic TechniquesAngiogenesis InhibitorsAnimalsAxitinibCell Line, TumorDisease Models, AnimalFemaleHumansMiceSpectrum AnalysisXenograft Model Antitumor AssaysAngiogenesis InhibitorsAxitinibImidazolesIndazolesOxygenAxitinibDiffuse optical spectroscopyExperimental tumorOptoacoustic imagingTumor angiogenesisTumor oxygenation

Identifiers

PMID41966749
PMCPMC13091365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.